Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC



Summary

Adding lurbinectedin to maintenance therapy significantly improved outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy, according to a recent study. The combination led to a statistically significant increase in progression-free survival (PFS) compared to placebo, delaying disease progression. While overall survival (OS) data is still maturing, the initial results suggest a positive trend. This research offers a promising new approach to extending the benefits of initial treatment and improving the prognosis for patients with this aggressive cancer. Further analysis of the OS data is eagerly awaited.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!